411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors

2008 ◽  
Vol 6 (12) ◽  
pp. 129 ◽  
Author(s):  
R. Salgia ◽  
A. Peterson ◽  
S. Eppler ◽  
W. Yu ◽  
B. Polite ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Locally Advanced ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose

Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3033-3033 ◽  
Author(s):  
A. L. Ho ◽  
J. C. Bendell ◽  
J. M. Cleary ◽  
G. K. Schwartz ◽  
H. A. Burris ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose

scholarly journals A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

2012 ◽  
Vol 31 (2) ◽  
pp. 409-416 ◽  
Author(s):  
Michael S. Gordon ◽  
David S. Mendelson ◽  
Mitchell Gross ◽  
Martina Uttenreuther-Fischer ◽  
Mahmoud Ould-Kaci ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Oral Treatment ◽  
Advanced Solid Tumors ◽  
Open Label ◽  
Dose Escalation Study ◽  
Once Daily ◽  
Label Dose

scholarly journals A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

2012 ◽  
Vol 31 (2) ◽  
pp. 399-408 ◽  
Author(s):  
John Marshall ◽  
Jimmy Hwang ◽  
Ferry A. L. M. Eskens ◽  
Herman Burger ◽  
Shakun Malik ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose

scholarly journals Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors

2016 ◽  
Vol 107 (10) ◽  
pp. 1477-1483 ◽  
Author(s):  
Hironobu Minami ◽  
Yuichi Ando ◽  
Brigette Buig Yue Ma ◽  
Jih‐ Hsiang Lee ◽  
Hiroyuki Momota ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Open Label ◽  
Dose Escalation Study ◽  
Asian Patients ◽  
Label Dose

A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3075-3075 ◽  
Author(s):  
K. P. Papadopoulos ◽  
D. S. Mendelson ◽  
A. W. Tolcher ◽  
A. Patnaik ◽  
H. A. Burris ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Proteasome Inhibitor ◽  
The Novel ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose
Sign in / Sign up

Export Citation Format

Share Document